Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.06 (-13.85%)

    Market Cap: $80.59M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Neumora Therapeutics, Inc. (NMRA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Neumora Therapeutics are Minerva Neurosciences (NERV), NRX Pharmaceuticals (NRXP) and Neuraxis (NRXS). By market cap, Neumora Therapeutics ranks 7th of the 13 companies on this page; Sionna Therapeutics, Inc. Common Stock (SION) is the largest at $150.63M.

    Peer Comparison

    NMRA's ROIC of -260.5% is below the peer median of -209.1%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Neumora Therapeutics (NMRA)$80.59MN/AN/A0.0%-260.5%0.0%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    Neuraxis, Inc. (NRXS)$76.93MN/A9.6x-144.4%-247.7%115.7%0.00%
    Tenax Therapeutics Inc (TENX)$73.77MN/AN/A0.0%N/A0.0%0.00%
    Cognition Therapeutics Inc (CGTX)$64.65MN/AN/A0.0%N/A0.0%0.00%
    Immunic Inc (IMUX)$102.61MN/AN/A0.0%N/A0.0%0.00%
    Voyager Therapeutics Inc (VYGR)$107.66MN/A4.0x0.0%N/A-70.0%0.00%
    Mink Therapeutics Inc (INKT)$47.95MN/A236.3x0.0%N/A0.0%0.00%
    Gain Therapeutics Inc (GANX)$46.31MN/AN/A0.0%-170.5%-100.0%0.00%
    Mereo BioPharma Group PLC ADR (MREO)$49.11MN/A61.3x0.0%-116.6%0.0%0.00%
    OUTLOOK THERAPEUTICS INC (OTLK)$100.54MN/AN/A0.0%-776.9%-99.4%0.00%
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    Peer median$86.26MN/A23.8x0.0%-209.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Neumora Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    Neuraxis, Inc. (NRXS)
    NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
    NRXS competitors
    Tenax Therapeutics Inc (TENX)
    Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing...
    TENX competitors
    Cognition Therapeutics Inc (CGTX)
    Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting...
    CGTX competitors
    Immunic Inc (IMUX)
    Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune...
    IMUX competitors
    Voyager Therapeutics Inc (VYGR)
    Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases.
    VYGR competitors
    Mink Therapeutics Inc (INKT)
    MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic...
    INKT competitors
    Gain Therapeutics Inc (GANX)
    Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding.
    GANX competitors
    Mereo BioPharma Group PLC ADR (MREO)
    Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases...
    MREO competitors
    OUTLOOK THERAPEUTICS INC (OTLK)
    Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic...
    OTLK competitors
    Sionna Therapeutics, Inc. Common Stock (SION)
    Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders...
    SION competitors

    Frequently Asked Questions About NMRA

    Who are Neumora Therapeutics' main competitors?

    The companies most similar to Neumora Therapeutics include Minerva Neurosciences (NERV), NRX Pharmaceuticals (NRXP), Neuraxis (NRXS), Tenax Therapeutics (TENX) and Cognition Therapeutics (CGTX), listed from the closest match.

    Who is Neumora Therapeutics' biggest competitor?

    Sionna Therapeutics, Inc. Common Stock (SION) is the largest of the similar companies at $150.63M; Minerva Neurosciences (NERV) is the closest match by business profile, size, sector and industry.

    How does NMRA stock compare with its competitors?

    NMRA's net margin is 0.0% against a peer median of 0.0%.

    Which of Neumora Therapeutics' competitors pays a higher dividend?

    Neumora Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Neumora Therapeutics bigger than its competitors?

    No. Neumora Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Sionna Therapeutics, Inc. Common Stock (SION) at $150.63M.